Wild Swing Trades 📈

HPE — Weak swing playbook 2026-06-22 • Personal Trading Playbook HPE — Weak swing playbook HPE — Expanded Analysis & Plan Risk Disclaimer: This is not financial advice. Trading involves substantial risk of loss. Only risk capital you can afford to lose. Past performance is not indicative of future results. Executive Summary Published: June 22, 2026 | Technical Analysis & Trade Plan PDUFA Catalyst HPE does not have traditional PDUFA or FDA regulatory milestones as it operates in enterprise infrastructure rather than biotech. Key near-term catalysts include follow-through from the June 1, 2026 Q2 earnings beat and raised guidance, the HPE Discover 2026 event (June 16, 2026) highlighting agentic AI and self-driving networks with NVIDIA, and ongoing AI order momentum expected to drive Q3 results. Additional potential triggers involve further networking-for-AI announcements and any updates on the Juniper integration syne...

Behind the Scenes of a Quant Lab: Building an Automated Trading Pipeline In modern swing trading, consistency, speed, and risk management separate profitable systems from chaotic discretionary trading. A highly sophisticated trading laboratory relies on automation to screen tickers, compute precise execution levels, estimate hit probabilities, and generate readable research reports. Here is a conceptual look inside a three-tier manufacturing assembly line for financial intelligence. Phase 1: Finding the Geometric Blueprint (The Backbone) The first layer of the system operates on the mathematical philosophy that markets have memory and move in structural cycles. It removes human emotion, rumors, and news from the equation, focusing strictly on the historical physics of price action. Locating Extremes: The system looks at a specific window of time to establish a definitive S...

CAT Surges to Fresh All-Time Highs: High-Probability Bullish Swing Setup on Strong Volume Breakout 2026-06-21 • Personal Trading Playbook CAT Surges to Fresh All-Time Highs: High-Probability Bullish Swing Setup on Strong Volume Breakout CAT — Expanded Analysis & Plan Risk Disclaimer: This is not financial advice. Trading involves substantial risk of loss. Only risk capital you can afford to lose. Past performance is not indicative of future results. Executive Summary Published: June 21, 2026 | Technical Analysis & Swing Trade Plan for CAT PDUFA Catalyst CAT has no traditional PDUFA or FDA regulatory milestones as an industrial equipment manufacturer. Key near-term catalysts instead include the Q2 2026 earnings release scheduled for August 4, 2026, with analyst EPS estimates around $6.16, and the CONEXPO 2026 trade show showcasing new AI and autonomy technologies. Additional momentum stems from ongoing AI infrastructure tailwinds and potential updates on the re...

SLI — Playbook & Thesis 2026-06-21 • Personal Trading Playbook SLI — Playbook & Thesis SLI — Expanded Analysis & Plan Risk Disclaimer: This is not financial advice. Trading involves substantial risk of loss. Only risk capital you can afford to lose. Past performance is not indicative of future results. Executive Summary Published: June 21, 2026 | Technical Analysis & Trade Plan PDUFA Catalyst No traditional FDA PDUFA dates apply as SLI is a lithium development company rather than a biotech. Key regulatory and project milestones include completion of the National Environmental Policy Act (NEPA) review on May 14, 2026, for the SWA Project. Remaining pre-FID workstreams target construction vendor contracting and environmental review in Q2 2026, advanced offtake negotiations by Q3 2026, and FID plus construction start targeted for 2026. First commercial production remains on track for 2029. Technical Analysis ...

VRDN — Playbook & Thesis 2026-06-21 • Personal Trading Playbook VRDN — Playbook & Thesis VRDN — Expanded Analysis & Plan Risk Disclaimer: This is not financial advice. Trading involves substantial risk of loss. Only risk capital you can afford to lose. Executive Summary Published: June 21, 2026 | Technical Analysis & Trade Plan PDUFA Catalyst The primary near-term catalyst is the FDA's target action date of June 30, 2026, for veligrotug's BLA in thyroid eye disease (TED) under Priority Review. The application was accepted in late 2025 and granted Breakthrough Therapy Designation earlier. No additional PDUFA extensions or delays have been announced as of June 21, 2026. Secondary readouts include topline Phase 3 data for elegrobart (VRDN-003) in active TED (REVEAL-1) expected in Q1 2026 and chronic TED (REVEAL-2) in Q2 2026, with potential BLA submission for the subcutaneous asset by year-en...

AMD: Momentum Breakout on Strong Volume — Moderate Conviction Swing Setup 2026-06-20 • Personal Playbook Blog • Swing Trade Setup AMD: Momentum Breakout on Strong Volume — Moderate Conviction Swing Setup AMD Risk Disclaimer: This is NOT financial advice. Trading involves substantial risk of loss, including possible loss of principal. Past performance is not indicative of future results. All analysis is for educational and personal use only. Do your own research and consult a licensed financial advisor before trading. Executive Summary Setup Type Swing Long Momentum breakout on strong volume Conviction Score 54 / 100 Moderate — mixed signals Position Size 1–2% Portfolio Starter / probe size only Time Horizon 2–4 Weeks Hold 10–28 days typical Risk / Reward 1 : 1.5 Blended (Peak 1:2.3) ...